Analyst Price Targets — LRMR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 30, 2026 11:06 am | Christopher Chen | Robert W. Baird | $5.00 | $3.20 | TheFly | Larimar Therapeutics price target lowered to $5 from $7 at Baird |
| March 3, 2026 2:30 pm | Laura Chico | Wedbush | $12.00 | $5.48 | StreetInsider | Larimar Therapeutics (LRMR) PT Raised to $12 at Wedbush |
| September 30, 2025 11:24 am | Joel Beatty | Robert W. Baird | $7.00 | $3.38 | TheFly | Larimar Therapeutics price target lowered to $7 from $10 at Baird |
| December 17, 2024 11:53 am | Edward White | H.C. Wainwright | $15.00 | $4.28 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Larimar Therapeutics (LRMR) |
| October 30, 2024 4:18 pm | Samantha Semenkow | Citigroup | $14.00 | $8.46 | StreetInsider | Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR), Opens 90-Day Upside Catalyst Watch |
| October 3, 2024 8:28 am | Laura Chico | Wedbush | $22.00 | $6.29 | TheFly | Wedbush bullish on Larimar Therapeutics, initiates with an Outperform |
| April 3, 2024 9:14 am | Joori Park | Leerink Partners | $25.00 | $7.57 | TheFly | Leerink bullish on Larimar Therapeutics, initiates with an Outperform |
| December 13, 2022 1:14 pm | — | Citigroup | $4.00 | $3.97 | Benzinga | Citigroup Initiates Coverage On Larimar Therapeutics with Neutral Rating, Announces Price Target of $4 |
Latest News for LRMR
NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, July 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LRMR.
U.S. House Trading
No House trades found for LRMR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.